Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives

Hypertension Clinical Trial

Official title:

Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives：a Multicenter Prospective Cohort Study （UPDATE-cohort）

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04531124
• Other study ID #: Huashan cardiology
• Status: Not yet recruiting
• Start date: September 1, 2020
• Est. completion date: February 28, 2026

Study information

• Verified date: August 2020
• Source: Huashan Hospital
• Contact: yong li, professor
• Phone: +86 13801753494
• Email: liyong606[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

this clinical trial is designed to study the cardiovascular and renal outcomes of hypertensives after an integrated management of blood pressure and other cardiometabolic risks. it is a multicenter prospective cohort study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30000
• Est. completion date: February 28, 2026
• Est. primary completion date: August 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Outpatients from departments of Cardiology, Endocrinology, Nephrology, Neurology, Geriatrics or General Internal Medicine.

2. Diagnosed as hypertension. Diagnostic criteria: 1)The office BP measured at the day of visit and at least one time before that day were above the cut-off values ( =140 mmHg SBP and/or =90 mmHg DBP); 2)for patients with normal BP at the day of visit, they should have already been given pre-treatment with antihypertensive drugs = 2 weeks.

3. Voluntary participation.

Exclusion Criteria:

1. Patients aged< 18 years old.

2. Patients without a definite diagnosis of hypertension(for instance, if the patient has been taking antihypertensive drugs irregularly, it is difficult to confirm the diagnosis of hypertension).

3. Patients with a definite diagnosis of secondary hypertension.

4. Patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome, severe hypothyroidism, terminal stage of malignancy, etc.

5. Patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis patients.

6. Patients diagnosed with mental abnormalities who are unable to complete the questionnaire.

7. Patients have once participated in this research during this study cycle(to avoid repeated participation).

Related Conditions & MeSH terms

• Cardiovascular Risk Factor
• Hypertension
• Kidney Diseases
• Renal Disease

Intervention

Other:
• integrated management
establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients

Locations

Country	Name	City	State
China	HuashanH	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	complex outcome	number of participants with 3P-MACE events(cardiovascular deaths, non-fatal myocardial infarction, non-fatal stroke)	follow-up 1 year
Primary	coronary angioplasty	number of participants with coronary angioplasty	follow-up 1 year
Primary	acute renal failure	number of participants with acute renal failure(eGFR decreases by 50% or <15ml/min/1.73m2, dialysis or renal death)	follow-up 1 year
Primary	acute heart failure	number of participants with acute heart failure(non-scheduled hospitalizations due to heart failure or required intravenous medication)	follow-up 1 year